Reslizumab
C38072/3084
Phase 3 small_molecule completed
Quick answer
Reslizumab for Eosinophilic Asthma is a Phase 3 program (small_molecule) at Teva Pharma GmbH with 5 ClinicalTrials.gov record(s).
Program details
- Company
- Teva Pharma GmbH
- Indication
- Eosinophilic Asthma
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed